There are no completed clinical trials studying these drugs specifically for endo
April 1, 2026: Lawsuits Involving Ozempic & Other GLP-1s Climb to Over 3,500 Ozempics manufacturer, Novo Nordisk, and one other GLP-1 company are facing about 3,546 lawsuits in an active, federally consolidated MDL filed by former patients and their loved ones
GLP-1 prescriptions for weight-loss In a separate analysis between 2020 and 2023, one HealthVerity closed claims dataset had more than 1.5 million patients who had at least one prescription for tirzepatide or semaglutide
difficile risk, and possible increased fracture risk Rebound acid hypersecretion occurs when stopping PPIs abruptly after more than 8 weeks of use
Lower blood pressure is only one part of semaglutides heart-related benefits
If not, we are here to educate you on the groundbreaking weight loss solution- Semaglutide